Source: BioSig Technologies, Inc.
BioSig Technologies,
Inc. (OTCQB: BSGM), a medical device company developing a proprietary
biomedical signal processing platform designed to address an unmet
technology need for the $4.6 billion electrophysiology (EP) marketplace,
today announced the appointment of Andrew Filler to the Company’s Board
of Directors.
Mr. Filler will be taking the seat of Dr. Jerome B. Zeldis, former Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, who has faithfully served the BioSig shareholders since 2014 and is now retiring from Board service.
“The quality of our Board of Directors is our biggest asset. The guidance that each Board member has brought to the Company throughout the years was, and remains, invaluable. As we progress towards commercialization, Andy’s deep understanding of technology and his impressive legal background will be key components for shaping our future licensing and business development strategy,” said Kenneth Londoner, Chairman and Chief Executive Officer of BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system, which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
No comments:
Post a Comment